THOR MEDICAL |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.03 NOK | +1.38% |
|
-3.92% | -20.16% |
| Feb. 28 | Transcript : Thor Medical ASA, H2 2023 Earnings Call, Feb 28, 2024 | |
| Feb. 14 | Thor Medical ASA Announces CEO Changes | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | - | Capitalization | 301M 3.22B |
|---|---|---|---|---|---|
| Net income 2022 | -311M -3.32B | Net income 2023 | -26M -278M | EV / Sales 2022 * | - |
| Net cash position 2022 | 98.56M 1.05B | Net cash position 2023 | 41.77M 446M | EV / Sales 2023 | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-8.49
x | Employees | 2 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 36.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on Thor Medical
More news
| 1 day | +1.38% | ||
| 1 week | -3.92% | ||
| Current month | -2.83% | ||
| 1 month | +0.39% | ||
| 3 months | -9.01% | ||
| 6 months | -25.90% | ||
| Current year | -20.16% |
1 week
1.01
1.08
1 month
1.011.13
Current year
0.851.53
1 year
0.852.30
3 years
0.852.30
5 years
0.852.30
10 years
0.852.30
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 1.03 | +1.38% | 143,374 |
| 24-05-15 | 1.016 | -1.36% | 295,615 |
| 24-05-14 | 1.03 | +1.58% | 86,663 |
| 24-05-13 | 1.014 | -2.31% | 146,661 |
| 24-05-10 | 1.038 | -3.17% | 221,898 |
Real-time Oslo Bors, May 16, 2024 at 10:45 am EDT
More quotes
Thor Medical ASA, formerly Nordic Nanovector ASA, is a Norway-based biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The Company is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.
Calendar
2024-08-29
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -20.16% | 22.6M | |
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
- Stock Market
- Equities
- NANOV Stock
